Remove Diabetes Remove Events Remove People Management
article thumbnail

FDA approves Novo Nordisk’s Wegovy for cardiovascular risk reduction

Pharmaceutical Business Review

As per the latest approval, the treatment is indicated for reducing risks of major adverse cardiovascular events (MACE) including cardiovascular mortality, non-fatal heart attack or myocardial infarction or non-fatal stroke. This label expansion follows a supplemental New Drug Application (sNDA) submitted by the company.

article thumbnail

Blood Sugar, Hashimoto’s, Ozempic, Metformin and Berberine

The Thyroid Pharmacist

There is a known link between Hashimoto’s and type 2 diabetes, with up to 30 percent of those with Hashimoto’s developing the condition. Conversely, patients with type 2 diabetes are at an increased risk of developing a thyroid disorder, especially women. Ozempic is a recent blockbuster drug with benefits for diabetes and weight.